Healthcare is the bottom line for safeguarding life; innovation is the engine for breaking through limitations. From the precise iteration of the scalpel to the intelligent empowerment of AI, from the precise support of policies to the cluster rise of industries, medical innovation has long transcended the single dimension of "technological upgrading," becoming a core force in reconstructing the healthcare service system, benefiting the health of all people, and enhancing the nation's medical competitiveness. Currently, China's medical innovation is undergoing a critical stage of transitioning from "catching up" to "keeping pace" and then to "leading the way," writing a contemporary answer of "technology for good, medicine to warm hearts" through policy support, technological breakthroughs, and in-depth clinical practice.
The continued breakthroughs in medical innovation rely heavily on robust institutional support. In recent years, the national government has released a series of policy dividends, establishing a comprehensive empowerment system encompassing "R&D-approval-implementation-widespread adoption," clearing obstacles and activating momentum for medical innovation. In January 2026, the National Healthcare Security Administration issued the "Guidelines for the Establishment of Price Items for Surgical and Treatment Assistance Medical Services (Trial)," establishing a unified price management framework at the national level for innovative technologies such as robotic surgery and remote surgery. This framework standardized 37 price items, balancing enterprise R&D cost recovery with patient accessibility through tiered pricing and clear consumable pricing rules, thus driving the industry from quantitative to qualitative transformation.
In the review and approval process, the National Medical Products Administration (NMPA) has continuously deepened reforms, establishing diversified channels such as special review and priority approval for innovation. This shifts the focus of regulatory services towards the R&D stage, forming a "one-company-one-policy, full-process guidance" working mechanism, significantly shortening the time to market for innovative medical devices. Data shows that in 2025, the National Medical Products Administration approved 76 domestically produced innovative medical devices for market launch, maintaining a high level for three consecutive years. These devices cover multiple cutting-edge fields such as artificial intelligence, tumor radiotherapy, and biomedical materials, accelerating the clinical application of more innovative achievements and benefiting people's lives. Simultaneously, the "1+3+N" multi-tiered medical security system is continuously improving, with standardized centralized procurement and regular medical insurance negotiations effectively reducing the prices of innovative products. This allows previously "unattainable" high-end medical technologies to gradually reach grassroots levels, achieving "supported innovation, pathways for implementation, and guaranteed accessibility."
Technological iteration is redefining the possibilities of healthcare. Today's medical innovation is no longer a breakthrough in a single technology, but a product of multidisciplinary integration. From clinical diagnosis and treatment to health management, from technology research and development to industrial application, the power of innovation is ubiquitous, continuously addressing clinical pain points and challenges.
Medical innovation is a long-term exploration concerning life, people's livelihoods, and the future. From policy support to technological breakthroughs, from industrial growth to in-depth clinical application, China's medical innovation is breaking boundaries and reshaping the landscape with a "multi-pronged approach and comprehensive efforts." It is not only about the iterative upgrading of high-end technologies, but also about the humanistic innovation of service models; it is not only a demonstration of industrial strength, but also a safeguard for the health of all people.
Standing at a new historical starting point, with the commencement of the 15th Five-Year Plan, continuous policy support, constant technological breakthroughs, and collaborative efforts across industries will undoubtedly lead to higher-quality development in China's medical innovation. Looking ahead, JinYi Internet anticipates more breakthroughs in core technologies, more innovative products reaching grassroots communities and benefiting the entire population, and more compassionate innovative initiatives taking root and flourishing. This will ensure that medical innovation truly becomes a powerful force in safeguarding life and health, enabling everyone to enjoy higher-quality, more precise, and more convenient medical services, moving towards the goal of a "Healthy China," and striving for a brighter future.
